Alvydas Česas
Klaipėda University(LT)Republic Klaipeda Hospital(LT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,270 cited
- → Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer(2022)87 cited
- → Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma(2006)77 cited
- → Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)(2020)36 cited
- → A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)(2016)31 cited
- → Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer(2014)12 cited
- → European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment(2020)12 cited
- → Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions(2024)11 cited
- [Combined treatment of esophageal cancer: a review].(2004)
- → RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis.(2015)8 cited